Finishing all six rounds of temozolomide linked to longer life
Original title: Completion of ≥6 cycles of adjuvant temozolomide is the strongest modifiable prognostic factor in glioblastoma: a 17-year real-world cohort of 319 glioma patients from a single Chinese center.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already standard care, and the study just looked back at patient records.
The short version
People with brain tumors who finished all six rounds of chemo lived longer.
What was studied. Doctors at one hospital in China looked back at records of 319 people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. 264 of them had full records and were studied closely. The team checked who finished 6 or more rounds of the drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary after radiation.
What they found. 133 of the patients died, which was 50.4%. Five years later, 81.8% of people with the lowest grade tumors were still alive. That number was 42.2% for grade III and 24.2% for grade IV. People who finished 6 or more rounds had their risk of dying cut in half. In glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, finishing 6 or more rounds lowered the risk of dying by 64%, while 1 to 5 rounds did no better than none.
What this means, and what it doesn't
What it could mean: Finishing the whole course of temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary may matter a lot. Stopping early may give up much of the benefit. If side effects make it hard to keep going, it is worth asking your care team what could help you finish.
What it doesn't mean: This does not prove the drug by itself caused the longer lives. The team only looked back at old records. People healthy enough to finish all six rounds may have done better for other reasons. The study authors say things they could not measure, like tumor gene type, may explain part of it. This is not a new treatment and it is not a cure. People with grade IV tumors still faced poor odds. Do not change your own plan without talking to your doctor.
Source: PubMed, September 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.